-
公开(公告)号:US07968094B2
公开(公告)日:2011-06-28
申请号:US12184205
申请日:2008-07-31
IPC分类号: A61K39/395
CPC分类号: C07K16/36 , A61K2039/505 , C07K16/467 , C07K2317/24 , C07K2319/00
摘要: Disclosed is a method for preventing or treating thrombosis in a mammal such as a primate and particularly a human patient. A preferred method includes administering to the mammal a therapeutically effective amount of at least one humanized antibody, chimeric antibody, or fragment thereof that binds specifically to human tissue factor (TF). Additional methods and kits are provided.
摘要翻译: 公开了一种预防或治疗哺乳动物如灵长类动物,特别是人类患者血栓形成的方法。 优选的方法包括向哺乳动物施用治疗有效量的与人组织因子(TF)特异性结合的至少一种人源化抗体,嵌合抗体或其片段。 提供其他方法和试剂盒。
-
公开(公告)号:US07824677B2
公开(公告)日:2010-11-02
申请号:US12136718
申请日:2008-06-10
IPC分类号: A61K39/395
CPC分类号: C07K16/36 , A61K38/00 , A61K39/395 , A61K2300/00
摘要: The invention includes methods of inhibiting blood coagulation using antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Methods of the invention can effectively inhibit blood coagulation in vivo. Antibodies used in the methods of the invention can bind native human TF, either alone or present in a TF:VIIa complex, effectively preventing factor X binding to TF or that complex, and thereby reducing blood coagulation. Preferred antibodies used in the methods of the invention specifically bind a conformational epitope predominant to native human TF, which epitope provides an unexpectedly strong antibody binding site.
摘要翻译: 本发明包括使用通过以高亲和性和特异性结合天然人TF提供优异抗凝血活性的抗体来抑制血液凝固的方法。 本发明的方法可有效抑制体内血液凝固。 用于本发明方法的抗体可以单独或存在于TF:VIIa复合物中的天然人TF结合,有效地防止因子X结合TF或该复合物,从而减少血液凝固。 用于本发明方法的优选抗体特异性结合构成天然人TF的构象表位,该表位提供了意想不到的强抗体结合位点。
-
公开(公告)号:US20090041766A1
公开(公告)日:2009-02-12
申请号:US12136718
申请日:2008-06-10
IPC分类号: A61K39/395
CPC分类号: C07K16/36 , A61K38/00 , A61K39/395 , A61K2300/00
摘要: The invention includes antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Antibodies of the invention can effectively inhibit blood coagulation in vivo. Antibodies of the invention can bind native human TF, either alone or present in a TF:VIIa complex, effectively preventing factor X binding to TF or that complex, and thereby reducing blood coagulation. Preferred antibodies of the invention specifically bind a conformational epitope predominant to native human TF, which epitope provides an unexpectedly strong antibody binding site.
-
公开(公告)号:US5986065A
公开(公告)日:1999-11-16
申请号:US814806
申请日:1997-03-10
IPC分类号: C12N15/09 , A61K38/00 , A61K39/395 , A61P7/02 , A61P9/00 , C07K16/28 , C07K16/36 , C07K16/46 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12P21/08 , C12Q1/68
CPC分类号: C07K16/36 , A61K39/395 , A61K38/00
摘要: The invention includes antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Antibodies of the invention can effectively inhibit blood coagulation in vivo. Antibodies of the invention can bind native human TF, either alone or present in a TF:VIIa complex, effectively preventing factor X binding to TF or that complex, and thereby reducing blood coagulation. Preferred antibodies of the invention specifically bind a conformational epitope predominant to native human TF, which epitope provides an unexpectedly strong antibody binding site.
-
5.
公开(公告)号:US06555319B2
公开(公告)日:2003-04-29
申请号:US09293854
申请日:1999-04-16
IPC分类号: G01N3353
CPC分类号: C07K16/36 , A61K38/00 , A61K39/395 , A61K2300/00
摘要: The invention includes antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Antibodies of the invention can effectively inhibit blood coagulation in vivo. Antibodies of the invention can bind native human TF, either alone or present in a TF:VIIa complex, effectively preventing factor X binding to TF or that complex, and thereby reducing blood coagulation. Preferred antibodies of the invention specifically bind a conformational epitope predominant to native human TF, which epitope provides an unexpectedly strong antibody binding site.
摘要翻译: 本发明包括通过以高亲和力和特异性结合天然人TF而提供优异抗凝血活性的抗体。 本发明的抗体可有效抑制体内血液凝固。 本发明的抗体可以单独或存在于TF:VIIa复合物中的天然人TF结合,有效地防止因子X结合TF或该复合物,从而减少血液凝固。 本发明优选的抗体特异性结合主要为天然人TF的构象表位,该表位提供意想不到的强抗体结合位点。
-
公开(公告)号:US07141656B2
公开(公告)日:2006-11-28
申请号:US09848164
申请日:2001-05-03
申请人: Peter R. Rhode , Jin-An Jiao , Martin Burkhardt , Hing C. Wong
发明人: Peter R. Rhode , Jin-An Jiao , Martin Burkhardt , Hing C. Wong
CPC分类号: C07K14/70539 , A01K2217/05 , A61K38/00 , A61K39/00 , A61K48/00 , A61K2039/53 , A61K2039/6043 , A61K2039/622 , C07K2319/00 , C07K2319/02
摘要: The present invention relates to novel complexes of major histocompability complex (MHC) molecules and uses of such complexes. In one aspect, the invention relates to loaded MHC complexes that include at least one MHC molecule with a peptide-binding groove and a presenting peptide non-covalently linked to the MHC protein. In another aspect, the invention features single chain MHC class II peptide fusion complexes with a presenting peptide covalently linked to the peptide binding grove of the complex. MHC complexes of the invention are useful for a variety of applications including: 1) in vitro screens for identification and isolation of peptides that modulate activity of selected T cells, including peptides that are T cell receptor antagonists and partial agonists, and 2) methods for suppressing or inducing an immune response in a mammal.
-
公开(公告)号:US07074904B2
公开(公告)日:2006-07-11
申请号:US09900379
申请日:2001-07-06
申请人: Hing C. Wong , Peter R. Rhode , Jon A. Weidanz , Susan Grammer , Ana C. Edwards , Pierre-Andre Chavaillaz , Jin-An Jiao
发明人: Hing C. Wong , Peter R. Rhode , Jon A. Weidanz , Susan Grammer , Ana C. Edwards , Pierre-Andre Chavaillaz , Jin-An Jiao
CPC分类号: C07K14/705 , A61K38/00 , A61K39/00 , A61K48/00 , C07K14/70532 , C07K14/70539 , C07K14/77 , C07K2319/00 , C12N2799/026 , Y10S530/868
摘要: The present invention relates to novel complexes of major histocompability complex (MHC) molecules and uses of such complexes. In particular, the invention relates to MHC fusion complexes that contain a MHC molecule with a peptide-binding groove and a presenting peptide covalently linked to the MHC protein. Fusion complexes of the invention are useful for a variety of applications including in vitro screens for identification and isolation of peptides that modulate activity of selected T cells, including peptides that are T cell receptor antagonists and partial agonists, methods of suppressing an immune response of a mammal and methods for inducing an immune response in a mammal.
-
公开(公告)号:US06309645B1
公开(公告)日:2001-10-30
申请号:US09067615
申请日:1998-04-28
申请人: Peter R. Rhode , Jin-An Jiao , Martin Burkhardt , Hing C. Wong
发明人: Peter R. Rhode , Jin-An Jiao , Martin Burkhardt , Hing C. Wong
IPC分类号: A61K3900
CPC分类号: C07K14/70539 , A01K2217/05 , A61K38/00 , A61K39/00 , A61K48/00 , A61K2039/53 , A61K2039/6043 , A61K2039/622 , C07K2319/00 , C07K2319/02
摘要: The present invention relates to novel complexes of major histocomability complex (MHC) molecules and uses of such complexes. In one aspect, the invention relates to loaded MHC complexes that include at least one MHC molecule with a peptide-binding groove and a presenting peptide non-covalently linked to the MHC protein. In another aspect, the invention features single chain MHC class II peptide fusion complexes with a presenting peptide covalently linked to the peptide binding grove of the complex. MHC complexes of the invention are useful for a variety of applications including: 1) in vitro screens for identification and isolation of peptides that modulate activity of selected T cells, including peptides that are T cell receptor antagonists and partial agonists, and 2) methods for suppressing or inducing an immune response in a mammal.
摘要翻译: 本发明涉及主要组织学复合物(MHC)分子的新型复合物和这种复合物的用途。 一方面,本发明涉及包含至少一个具有肽结合槽的MHC分子和与MHC蛋白非共价连接的呈递肽的负载的MHC复合物。 另一方面,本发明的特征在于具有与复合物的肽结合树共价连接的呈递肽的单链MHC II类肽融合复合物。 本发明的MHC复合物可用于多种应用,包括:1)用于鉴定和分离调节所选T细胞活性的肽的体外筛选,包括作为T细胞受体拮抗剂和部分激动剂的肽,以及2) 抑制或诱导哺乳动物的免疫应答。
-
公开(公告)号:US07199113B2
公开(公告)日:2007-04-03
申请号:US11005871
申请日:2004-12-06
IPC分类号: A01N57/00 , A61K31/675
CPC分类号: C07F9/3873 , A61K31/66 , A61K31/663 , A61K31/675 , C07F9/386
摘要: The invention includes pharmaceutically active compounds and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are particularly useful for treatment or prophylaxis of undesired thrombosis.
-
公开(公告)号:US06849617B2
公开(公告)日:2005-02-01
申请号:US10445205
申请日:2003-05-23
IPC分类号: C07D249/18 , A61K31/00 , A61K31/137 , A61K31/138 , A61K31/15 , A61K31/165 , A61K31/166 , A61K31/17 , A61K31/175 , A61K31/196 , A61K31/24 , A61K31/245 , A61K31/381 , A61K31/415 , A61K31/4192 , A61K31/422 , A61K31/423 , A61K31/47 , A61K31/4704 , A61K31/473 , A61K31/495 , A61K31/506 , A61K31/6615 , A61K45/00 , A61K45/06 , A61P7/02 , A61P9/00 , A61P9/10 , A61P29/00 , A61P31/04 , A61P35/00 , A61P37/06 , C07C217/30 , C07C251/24 , C07C275/40 , C07D215/38 , C07D221/14 , C07D231/38 , C07D263/56 , C07D263/60 , C07D295/02 , C07D333/76 , C07D403/14 , C07F9/38 , A61K31/33 , C07D213/00 , C07D217/00
CPC分类号: A61K31/663 , A61K31/00 , A61K31/137 , A61K31/165 , A61K31/166 , A61K31/17 , A61K31/196 , A61K31/381 , A61K31/415 , A61K31/4192 , A61K31/423 , A61K31/4704 , A61K31/473 , A61K31/495 , A61K31/506 , A61K45/06 , C07C217/30 , C07C251/24 , C07C275/40 , C07C2601/02 , C07C2601/08 , C07F9/3873 , Y10S514/888
摘要: The invention includes pharmaceutically active compounds and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are particularly useful for treating or prophylaxis of undesired thrombosis.
摘要翻译: 本发明包括药物活性化合物和治疗方法以及利用或包含一种或多种这类化合物的药物组合物。 本发明的化合物特别可用于治疗或预防不期望的血栓形成。
-
-
-
-
-
-
-
-
-